PURPOSE: The aim of this study was to estimate the 1-year prevalence of levothyroxine-treated hypothyroidism in Finland. METHODS: Data on all individuals who had regularly purchased levothyroxine sodium tablets during 2007 were retrieved from the nationwide Finnish Drug Prescription Database. The prevalence rates and 95% confidence intervals were calculated per 100 individuals assuming a Poisson distribution. RESULTS: In total, 189,027 individuals (84% female) were identified as using levothyroxine tablets, which translated into a 1-year prevalence of hypothyroidism of 3.6%. The disease was notably more common in females (5.9%) than in males (1.2%), with a gender prevalence rate ratio (PRR) of 4.5. Prevalence increased with age. A comparison of five university hospital districts revealed that the prevalence rates were fairly stable regionally, with the lowest rate being 3.1% and the highest 4.4%; the regional PRR was 1.3. CONCLUSIONS: To the best of our knowledge, this nationwide prescription study includes the largest population of reported levothyroxine users to date. This comprehensive data justifies estimating the gender- and age-specific prevalence of hypothyroidism in Finland.
PURPOSE: The aim of this study was to estimate the 1-year prevalence of levothyroxine-treated hypothyroidism in Finland. METHODS: Data on all individuals who had regularly purchased levothyroxine sodium tablets during 2007 were retrieved from the nationwide Finnish Drug Prescription Database. The prevalence rates and 95% confidence intervals were calculated per 100 individuals assuming a Poisson distribution. RESULTS: In total, 189,027 individuals (84% female) were identified as using levothyroxine tablets, which translated into a 1-year prevalence of hypothyroidism of 3.6%. The disease was notably more common in females (5.9%) than in males (1.2%), with a gender prevalence rate ratio (PRR) of 4.5. Prevalence increased with age. A comparison of five university hospital districts revealed that the prevalence rates were fairly stable regionally, with the lowest rate being 3.1% and the highest 4.4%; the regional PRR was 1.3. CONCLUSIONS: To the best of our knowledge, this nationwide prescription study includes the largest population of reported levothyroxine users to date. This comprehensive data justifies estimating the gender- and age-specific prevalence of hypothyroidism in Finland.
Authors: T Bjoro; J Holmen; O Krüger; K Midthjell; K Hunstad; T Schreiner; L Sandnes; H Brochmann Journal: Eur J Endocrinol Date: 2000-11 Impact factor: 6.664
Authors: P Laurberg; K M Pedersen; A Hreidarsson; N Sigfusson; E Iversen; P R Knudsen Journal: J Clin Endocrinol Metab Date: 1998-03 Impact factor: 5.958
Authors: Joseph G Hollowell; Norman W Staehling; W Dana Flanders; W Harry Hannon; Elaine W Gunter; Carole A Spencer; Lewis E Braverman Journal: J Clin Endocrinol Metab Date: 2002-02 Impact factor: 5.958
Authors: Per Wändell; Axel C Carlsson; Martin J Holzmann; Johan Ärnlöv; Jan Sundquist; Kristina Sundquist Journal: Am J Cardiol Date: 2017-08-30 Impact factor: 2.778
Authors: Hanneke J C M Wouters; Sandra N Slagter; Anneke C Muller Kobold; Melanie M van der Klauw; Bruce H R Wolffenbuttel Journal: PLoS One Date: 2020-11-25 Impact factor: 3.240
Authors: Camilla Janett-Pellegri; Lea Wildisen; Martin Feller; Cinzia Del Giovane; Elisavet Moutzouri; Oliver Grolimund; Patrick Walter; Gérard Waeber; Pedro Marques-Vidal; Peter Vollenweider; Nicolas Rodondi Journal: PLoS One Date: 2021-12-20 Impact factor: 3.240